BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR-1139 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR-1139\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07719530-31@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07719530)
DESCRIPTION:SHR-1139\, phase 2\, Psoriasis.\nStudy: Phase II Clinical Trial
  of SHR-1139 Injection in Patients With Psoriasis\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/shr-1139#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07719530
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444684-31@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07444684)
DESCRIPTION:SHR-1139\, phase 2.\nStudy: A Study to Evaluate SHR-1139 Inject
 ion in Patients With Pyoderma Gangrenosum\nEstimated primary completion: J
 une 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-1139#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT074446
 84
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07758075-31@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07758075)
DESCRIPTION:SHR-1139\, phase 2\, Psoriasis.\nStudy: A Phase II Clinical Stu
 dy to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients W
 ith Plaque Psoriasis\nEstimated primary completion: July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/shr-1139#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07758075
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07232576-31@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07232576)
DESCRIPTION:SHR-1139\, phase 2\, Ulcerative Colitis.\nStudy: A Phase 2 Stud
 y to Evaluate the Efficacy\, Safety and Pharmacokinetics of SHR-1139 in Pa
 tients With Moderate-to-severe Active Ulcerative Colitis\nEstimated primar
 y completion: August 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/shr-1139#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07232576
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923851-31@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07923851)
DESCRIPTION:SHR-1139\, phase 2.\nStudy: A Trial Evaluating the Efficacy and
  Safety of SHR-1139 Injection in Adult Patients With Palmoplantar Pustulos
 is\nEstimated primary completion: November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/shr-1139#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07923851
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07337564-31@assetmemo.bio
DTSTAMP:20261121T005602Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07337564)
DESCRIPTION:SHR-1139\, phase 2.\nStudy: A Clinical Study Evaluating the Eff
 icacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative P
 yoderma Gangrenosum\nEstimated primary completion: December 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/shr-1139#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07337564
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
